B. Riley Wealth Advisors Inc. Acquires 1,662 Shares of DexCom, Inc. (NASDAQ:DXCM)

B. Riley Wealth Advisors Inc. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 42.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,590 shares of the medical device company’s stock after acquiring an additional 1,662 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in DexCom were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Blue Whale Capital LLP increased its holdings in DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC increased its stake in shares of DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Brooktree Capital Management bought a new stake in shares of DexCom during the 3rd quarter valued at $683,000. National Pension Service raised its position in shares of DexCom by 4.1% during the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in shares of DexCom during the 3rd quarter valued at $650,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 5.6 %

DXCM stock opened at $80.04 on Friday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm’s 50-day moving average is $74.53 and its 200 day moving average is $83.10. The company has a market capitalization of $31.26 billion, a PE ratio of 47.93, a P/E/G ratio of 2.46 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Analysts Set New Price Targets

A number of research firms recently commented on DXCM. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.